What Protein Does Lipitor Target?
Lipitor (atorvastatin) inhibits HMG-CoA reductase, the enzyme that limits the rate of cholesterol synthesis in the liver. This protein converts HMG-CoA to mevalonate, a key step in the mevalonate pathway producing cholesterol. By blocking it, Lipitor reduces hepatic cholesterol production, prompting the liver to clear more low-density lipoprotein (LDL) cholesterol from the blood.
How Does This Mechanism Lower Cholesterol?
HMG-CoA reductase inhibition lowers intracellular cholesterol levels, activating SREBP-2 transcription factors. These upregulate LDL receptor expression on liver cells, increasing LDL uptake and clearance from circulation. Statins like Lipitor thus primarily reduce LDL cholesterol by 30-50% in most patients, with less impact on triglycerides or HDL.
Why Focus on HMG-CoA Reductase Specifically?
This enzyme controls the cholesterol biosynthesis bottleneck; excess activity drives hypercholesterolemia. Targeting it avoids broader pathway disruption while effectively mimicking dietary cholesterol restriction. No other proteins are directly inhibited by Lipitor for its cholesterol-lowering effect.
What Happens If HMG-CoA Reductase Mutates or Overexpresses?
Rare genetic variants in the HMGCR gene can reduce statin efficacy, leading to statin resistance. Patients may need higher doses or alternatives like ezetimibe, which targets NPC1L1 instead.
How Do Other Statins Compare?
All statins (e.g., rosuvastatin/Crestor, simvastatin/Zocor) inhibit the same protein but differ in potency and lipophilicity. Atorvastatin is moderately potent with good liver selectivity.
Lipitor Patent and Generic Availability
Lipitor's key patents on atorvastatin expired in 2011 in the US, enabling generics. Remaining formulation patents ended by 2017. Check current status on DrugPatentWatch.com.
Sources:
[1] PubMed: Statin mechanism review
[2] FDA Lipitor label
[3] DrugPatentWatch: Lipitor patents